Evaluation of a sensitive colorimetric FXIII incorporation assay. Effects of FXIII Val34Leu, plasma fibrinogen concentration and congenital FXIII deficiency

Thrombosis Research

Volumn 102, Issue 1, 2001, Pages 81-91

  Wilmer, Marianne ^a   Rudin, Karin ^a   Kolde, Hans Jürgen ^a   Poetzsch, Bernd ^b   Lenz, Wolfgang ^b   Moessmer, Georg ^c   Meili, Esther ^d   Egbring, Roland ^e   Gempeler Messina, Patrizia ^a   Gempeler, Mathias ^a   Bastian, Sonja ^f   Kohler, Hans Peter ^g  

^a Pentapharm Ltd   (Switzerland)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY HOSPITAL MARBURG   (Germany)

^f Progen Immuno Diagnostika   (Germany)

^g UNIVERSITY OF BERN   (Switzerland)

Author keywords

FXIII; FXIII activity; FXIII deficiency; Incorporation assay; Substitution therapy; Thrombosis; Transglutaminase; Val34Leu

Indexed keywords

5 (BIOTINAMIDO)PENTYLAMINE; AMINE; AMMONIA; BLOOD CLOTTING FACTOR 13; FIBRIN; FIBRINOGEN; GLUTAMINE DERIVATIVE; GLYCINE ETHYL ESTER; LEUCINE; PEPTIDE DERIVATIVE; PROTEIN SUBUNIT; UNCLASSIFIED DRUG; VALINE;

ALPHA CHAIN; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD CLOTTING FACTOR 13 DEFICIENCY; CLINICAL TRIAL; COLORIMETRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOGEN BLOOD LEVEL; GENOTYPE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHOTOMETRY; PRIORITY JOURNAL;

AMINES; AMINO ACID SUBSTITUTION; AMMONIA; CHROMOGENIC COMPOUNDS; CLINICAL CHEMISTRY TESTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XIII; FACTOR XIII DEFICIENCY; FIBRINOGEN; HUMANS; KINETICS; LEUCINE; POINT MUTATION; SENSITIVITY AND SPECIFICITY; VALINE;

EID: 0035311193     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(01)00224-9     Document Type: Article

References (41)

1. Titration of the acceptor cross-linking sites in fibrin
2. Determination of factor XIII activity and of factor XIII inhibitors using an ammonium-sensitive electrode
3. Human factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin
4. Transglutaminases: Protein crosslinking enzymes in tissue and body fluids
5. Human factor XIII fibrin stabilising factor
6. 2-plasmin inhibitor to fibrinogen by fibrin-stabilizing factor
7. Human procarboxipeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin
8. Association of a common polymorphism in the factor XIII gene with myocardial infarction
9. Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males
10. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction
11. Association of a common polymorphism in the factor XIII gene with venous thrombosis
12. Factor XIIIVal34Leu is a genetic factor involved in the aetiology of venous thrombosis
13. FXIII Val 34 Leu: A novel association with primary intracerebral hemorrhage
14. Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age, smoking and hypertension
15. Blood coagulation F XIII: Determination by clot stability assays
16. A photometric assay for blood coagulation factor XIII
17. Ammonia production during clot retraction and its use in assay of fibrinoligase
18. A filter assay for transamidating enzymes using radioactive amine substrates
19. Transamidating enzymes. A continuous fluorescent method suited for automating measurements of factor XIII in plasma
20. New colored and fluorescent amine substrates for activated fibrin stabilizing factor (Factor XIIIa) and for transglutaminase
21. Colometric assay of blood coagulation factor XIII in plasma
22. A microtiter plate transglutaminase assay utilizing 5-(biotinamido) pentylamine as substrate
23. A microtiter assay for factor XIII using fibrinogen and biotincadaverine as substrates
24. A common coding polymorphism in the factor XIII A-subunit gene (FXIIIVal34Leu) affects cross-linking activity
25. Optimisation of a functional incorporation assay for FXIII
26. The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity
27. Kinetic determination of blood coagulation factor XIII in plasma
28. Diagnostic and genetic studies on fibrin-stabilizing factor with a new assay based on amine incorporation
29. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure
30. Factor V is a substrate for the transamidase factor XIIIa
31. 2-plasmin inhibitor
32. Cross-linking of fibronectin to collagen by blood coagulation factor XIIIa
33. Tissue transglutaminase and factor XIII in cartilage and bone remodelling
34. Pathogenesis of primary pulmonary embolism: Impact of the factor XIII:Val34Leu polymorphism
35. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies
36. The effect of factor XIII on bleeding in coronary surgery
37. Analytical and clinical utility of a photometric assay for blood coagulation factor XIII
38. Novel aspects of blood coagulation factor XIII. Structure, distribution, activation, and function
39. Wound healing at the site of microvascular anastomosis: Fibrin-stabilizing factor XIII administration and its effects
40. Deficiency in the A-subunit of coagulation factor XIII: Two novel point mutations demonstrate different effects on transcript levels
41. Novel polymorphisms and haplotypes in the human coagulation factor XIII A-subunit gene